<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214717</url>
  </required_header>
  <id_info>
    <org_study_id>2019-008</org_study_id>
    <nct_id>NCT04214717</nct_id>
  </id_info>
  <brief_title>Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor</brief_title>
  <acronym>DC-CIK</acronym>
  <official_title>Study of Dendritic Cell-activated Cytokine-induced Killer Cell Combined With Chemotherapy for Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yantai Yuhuangding Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yantai Yuhuangding Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With
      chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in group A will receive 4 cycles of DC-CIK treatments within 8 months. Patients in
      group B will have no immunotherapy. Chemotherapy are available in both groups.The
      investigators want to evaluate the efficacy of combination of DC-CIK with chemotherapy in
      patients with treatment-refractory solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rates (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>Disease Control Rates (CR + PR + SD), according to solid tumor response evaluation standard (response evaluation criteria in solid tumors, RECIST).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Combination of DC-CIK with chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive DC-CIK treatments combined with Chemotherapy .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will only receive Chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>DC-CIK combined with Chemotherapy</intervention_name>
    <description>Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.</description>
    <arm_group_label>Combination of DC-CIK with chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Patients will only receive Chemotherapy.</description>
    <arm_group_label>Chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with treatment-refractory advanced solid cancer can not accept operation;

          2. Age 18 to 75 years;

          3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points;

          4. estimate survival &gt; 3 months;

          5. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count (PLT)≥ 80×109/L;
             Alanine amino transferase (ALT) and aspartate amino transferase (AST)≤ 2 times of
             normal upper value; Serum Cr ≤ 2 normal upper value;

          6. Without any other malignant disease;

          7. With more than one scalable lesions;

          8. Patients Voluntary attempt, and informed consent;

          9. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the preparative chemotherapy on the fetus.

        Exclusion Criteria:

          1. Patients who do not conform to the inclusion criteria;

          2. Patients with uncontrolled infection; underlying disease that was severe or
             life-threatening (such as uncontrolled brain metastasis );

          3. Patients who were pregnant or lactating;

          4. ECOG perform status ≥ 2;4.

          5. Other situations that the researchers considered unsuitable for this study (such as
             mental illness, drug abuse, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Chen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yantai Yuhuangding Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peiwen Lian, PhD</last_name>
    <phone>+0086 5356691999</phone>
    <phone_ext>82708</phone_ext>
    <email>peiwen.lian@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Chen, PhD</last_name>
    <phone>+0086 5356691999</phone>
    <phone_ext>81511</phone_ext>
    <email>chenjianyt@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiwen Lian, PhD</last_name>
      <phone>+0086 5356691999</phone>
      <phone_ext>82708</phone_ext>
      <email>peiwen.lian@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yantai Yuhuangding Hospital</investigator_affiliation>
    <investigator_full_name>Peiwen Lian</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

